Hims & Hers Health Inc. ($HIMS) Stock Forecast: Down 7.7% Today

What is Hims & Hers Health Inc.?

Hims & Hers Health, Inc. (HIMS) is a company focusing on technology-driven accessibility to healthcare, providing services in areas such as men's health and hormone therapies. The stock experienced a notable decrease in value today.

Why is Hims & Hers Health Inc. going down?

HIMS stock is down 7.7% on Oct 16, 2025 19:06

• The recruitment of a new technology chief and the entry into men's health and hormone therapies were seen as positive developments for HIMS.
• However, worries about escalating expenses and regulatory obstacles could have influenced the stock's decline.
• The overall market downturn might have also impacted the decrease in HIMS stock value.
• Investors could be exercising caution regarding the company's capacity to overcome challenges and sustain its growth trajectory amidst growing costs and regulatory uncertainties.

HIMS Price Chart

HIMS Technical Analysis

HIMS News

Hims & Hers Elevates Technology-Driven Healthcare Accessibility

HIMS boosts AI-led care with new technology chief, hormone therapies and a global push via its ZAVA acquisition.

https://www.zacks.com/stock/news/2770464/hims-hers-elevates-technology-driven-healthcare-accessibility

Hims & Hers Gains 3.8% in 3 Months: Time to Hold the Stock or Sell?

HIMS expands into men's health and hormones, but rising costs and regulatory hurdles threaten its momentum.

https://www.zacks.com/stock/news/2768635/hims-hers-gains-38-in-3-months-time-to-hold-the-stock-or-sell

Hims & Hers Health, Inc. ( HIMS ) Dips More Than Broader Market: What You Should Know

Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $53.96, signifying a -7.36% move from its prior day's close.

https://www.zacks.com/stock/news/2766640/hims-hers-health-inc-hims-dips-more-than-broader-market-what-you-should-know

Trending Today

XRP ($XRP) Crypto Forecast: Down 5.1% Today

ZCash ($ZEC) Crypto Forecast: Down 10.2% Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.0% Today

Datadog Inc. ($DDOG) Stock Forecast: Down 5.6% Today

QuantumScape Corp. ($QS) Stock Forecast: Down 14.8% Today

Upstart Holdings Inc. ($UPST) Stock Forecast: Down 5.1% Today

SoFi Technologies Inc. ($SOFI) Stock Forecast: Down 5.2% Today

Hims & Hers Health Inc. ($HIMS) Stock Forecast: Down 7.7% Today

Fifth Third Bancorp ($FITB) Stock Forecast: Down 5.1% Today

Hewlett Packard Enterprise Company ($HPE) Stock Forecast: Down 11.9% Today

Hims & Hers Health Inc. Price History

10.09.2025 - HIMS Stock was down 5.4%

• The bearish movement in HIMS stock today could be due to profit-taking by investors after a period of strong growth.
• Despite the expansion of its telehealth platform and international growth plans, investors may have been expecting even more significant developments or revenue projections.
• Market sentiment towards telehealth companies may have shifted, impacting HIMS stock negatively despite its positive news.

18.08.2025 - HIMS Stock was up 5.8%

• The uptick in HIMS stock today can be credited to the company's expansion of AI and technology focus to advance digital care, demonstrating a dedication to innovation and growth within the digital healthcare sector.
• Investors appear to be overlooking FDA scrutiny regarding misleading claims about its semaglutide products, choosing instead to focus on the company's strategic efforts and potential for expansion, which has bolstered confidence in the stock.
• HIMS' substantial growth over the past 6 months may have also influenced today's positive movement, propelled by new product releases, international expansion strategies, and strong subscriber-driven growth, despite concerns about escalating costs impacting gross margins.

26.08.2025 - HIMS Stock was up 7.7%

• HIMS stock experienced a strong bullish movement despite closing at a lower price than the previous day.
• Investor interest in HIMS was potentially sparked by a comparison with Doximity, leading to the bullish trend.
• The slight decline in HIMS stock price may be attributed to profit-taking following a period of growth.
• Optimism among investors regarding HIMS's future earnings growth and platform expansion may be fueling the overall bullish sentiment.

30.08.2025 - HIMS Stock was down 5.1%

• The release of the YieldMax HIMS Option Income Strategy ETF might have prompted heightened selling activity in HIMS shares, potentially due to investor interest shifting to this new ETF.
• A comparison of HIMS with Doximity in terms of earnings growth and platform expansion could have underscored areas where HIMS is trailing, sparking investor unease and contributing to the bearish trend.
• The more pronounced drop in HIMS compared to the wider market suggests specific company-related factors, such as performance metrics or market sentiment, might have played a role in the negative stock movement.

16.09.2025 - HIMS Stock was down 7.7%

• The recruitment of a new technology chief and the entry into men's health and hormone therapies were seen as positive developments for HIMS.
• However, worries about escalating expenses and regulatory obstacles could have influenced the stock's decline.
• The overall market downturn might have also impacted the decrease in HIMS stock value.
• Investors could be exercising caution regarding the company's capacity to overcome challenges and sustain its growth trajectory amidst growing costs and regulatory uncertainties.

24.08.2025 - HIMS Stock was down 5.2%

• HIMS stock saw a significant dip of -2.95% compared to the previous day's close.
• The comparison to Oscar Health Inc's potential "moonshot" amidst ACA subsidy chatter could have led investors to shift focus, impacting HIMS negatively.
• The overall bearish market sentiment might have exacerbated the stock's decline, as investors may have been more risk-averse and opted to sell off their positions in HIMS.
• The combination of internal company performance and external market conditions likely contributed to the pronounced bearish movement in HIMS stock today.

19.08.2025 - HIMS Stock was up 5.7%

• The bullish movement in Hims & Hers Health's stock could be attributed to the company's expansion of its AI and technology focus to advance digital care. This move indicates a strategic shift towards enhancing its digital healthcare offerings, which might have resonated positively with investors.
• The news about FDA's warning regarding misleading claims related to Hims & Hers' semaglutide products could have initially caused some uncertainty in the market. However, the company's ability to respond within the given timeframe and potentially address the concerns may have reassured investors, leading to the bullish momentum.
• The comparison of Oscar Health Inc. to Hims & Hers Health in terms of a potential "moonshot" and the buzz around ACA subsidy chatter could have also generated positive sentiment around HIMS stock, especially amidst the broader healthcare policy discussions.
• Despite the options frenzy and bearish tendencies highlighted in the analysis, the overall market sentiment seems to have favored Hims & Hers Health today, possibly driven by the company's strategic initiatives and market positioning in the digital healthcare space.

03.09.2025 - HIMS Stock was down 5.0%

• The method of increasing health access through subscription revenues did not sway the stock's performance in a positive direction.
• Contrasts with other value stocks like OMCL prompted discussions on HIMS' valuation and future outlook.
• Market sentiment was pessimistic towards HIMS, with major investors showing a bearish outlook.
• The launch of a new ETF by YieldMax linked to HIMS did not notably boost the stock's performance.

15.09.2025 - HIMS Stock was up 6.5%

• The positive movement in HIMS stock today reflects the company's strategic expansion into men's health and hormones, which could attract new customers and boost revenue.
• Despite challenges such as regulations and costs, the market shows confidence in HIMS' future, particularly following its telehealth platform expansion.
• Investors see potential in HIMS due to its innovative telehealth services and commitment to increasing healthcare access through technology.
• The recent stock drop in HIMS may have been a momentary blip, likely more affected by general market trends than inherent issues with the company.

14.09.2025 - HIMS Stock was down 5.3%

• HIMS stock price dropped by -7.36% from the previous day's close.
• Despite the company's efforts to expand its telehealth platform and enter international markets, market conditions or specific company events may have led to the negative investor response.
• The bearish movement might also be influenced by investors taking profits after a growth period or concerns regarding the company's future profitability.
• Investors should monitor HIMS closely for any developments to gauge the continuation of the bearish trend or potential recovery opportunities.

16.08.2025 - HIMS Stock was down 5.7%

• Concerns were raised by the FDA regarding Hims & Hers' claims about semaglutide, potentially misleading consumers and prompting the possibility of legal repercussions if not promptly addressed.
• Despite recent AI technology advancements and digital care expansion, the stock encountered a significant decline due to regulatory obstacles.
• The company's robust subscriber-driven growth and global expansion aspirations were overshadowed by increasing costs, affecting gross margins and investor attitudes.
• The market's response to the developments led to a negative impact on HIMS stock, resulting in a 3.73% decline despite overall market gains.

16.08.2025 - HIMS Stock was down 7.5%

• The company has been diversifying its focus towards AI and technology to elevate digital healthcare provision, showcasing a shift towards technology-centric healthcare solutions.
• Despite an impressive 64.1% climb in the last half-year driven by new product introductions and plans for international expansion, escalating expenses have been straining the company's profit margins.
• The stock witnessed a decrease of -3.73% despite broader market advancements, hinting at potential investor apprehensions regarding the company's cost management capabilities.
• Despite welcoming a new CTO and sustained growth fueled by subscribers, these developments may not have been sufficient to counteract the adverse effects of rising expenses on investor confidence, leading to the decline in the stock value.